Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02224430 · ClinicalTrials.gov registry record
Prediction of Relapse in Schizophrenia/Schizoaffective Disorder With Smartphones and On-body Sensors
A clinical trial, sponsored by University of Alabama at Birmingham.
- Completed
- Registry status
- 40
- Enrollment target
NCT02224430 is a clinical trial that has completed, run by University of Alabama at Birmingham. The registered enrollment target is 40 participants.
The verdict
NCT02224430 has completed, sponsored by University of Alabama at Birmingham.
- COMPLETED
- Registry status
- 40 participants
- Enrollment target
Study Summary
This study is dedicated to achieving a better understanding of how to identify patterns that indicate someone might be at high risk for relapse in schizophrenia or schizoaffective disorder. The investigators are utilizing smartphone technology along with on body sensors to achieve this goal. The study will observe participants behavior in their natural environment for a period of 16 weeks or until a signal of relapse is obtained. Participants will also complete scales in a clinical research environment biweekly.
Interventions
- DEVICE schizophrenia/schizoaffective disorder.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2014-08 |
| Est. Completion | 2019-12-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02224430
The ClinicalTrials.gov registry entry for NCT02224430 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which schizophrenia/schizoaffective disorder. is the first listed.
NCT02224430 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02224430 about?
NCT02224430 is a clinical study titled "Prediction of Relapse in Schizophrenia/Schizoaffective Disorder With Smartphones and On-body Sensors". This study is dedicated to achieving a better understanding of how to identify patterns that indicate someone might be at high risk for relapse in schizophrenia or schizoaffective disorder. The investigators are utilizing smartphone technology along with on body sensors to achieve this goal. The stu...
What is the current status of trial NCT02224430?
This trial is currently completed. The enrollment target is 40 participants. The study started on 2014-08. Estimated completion is 2019-12-31.
What interventions are being tested in trial NCT02224430?
The interventions under investigation include: schizophrenia/schizoaffective disorder. (DEVICE).
Who is sponsoring clinical trial NCT02224430?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.